Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- Imara previously announced data from the second planned interim analysis of its ongoing Phase 2a clinical trial of IMR-687 in adult patients with SCD.
- Imara expects to report top-line data from this Phase 2a clinical trial in the fourth quarter of 2020.
- The global, randomized, double-blind, placebo-controlled, multicenter Ardent Phase 2b clinical trial will enroll approximately 99 adult patients with sickle cell disease (SCD).